Updated to include: approval of Novavax, clarification around deferral after COVID-19 infection, one-off programme for 5 to 11 year olds who are not in clinical risk groups, advice on use of the paediatric formulation in those aged 12 years, spring booster recommendations (including flexibility around timing) and expectations for an autumn booster, clarification of the management of individuals with a history of allergic reactions, updated advice on management of people who have ITP following vaccination. Updated to include information on the autumn programme and variant vaccines, and further clarification of information on revaccination and capillary leak syndrome. Updated to include approval of Pfizer bivalent vaccine and further clarification around vaccination of under 12 year olds.
0 Comments
Leave a Reply. |